Your browser doesn't support javascript.
loading
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig, Heinz; Greil, Richard; Masszi, Tamas; Spicka, Ivan; Shpilberg, Ofer; Hajek, Roman; Dmoszynska, Anna; Paiva, Bruno; Vidriales, María-Belén; Esteves, Graca; Stoppa, Anne Marie; Robinson, Don; Chaturvedi, Shalini; Ataman, Ozlem; Enny, Christopher; Feng, Huaibao; van de Velde, Helgi; Viterbo, Luisa.
Affiliation
  • Ludwig H; c/o First Department of Medicine, Centre for Oncology, Haematology and Palliative Care, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
  • Greil R; Landeskrankenhaus, Universitätsklinik für Innere Medizin III, Salzburg, Austria.
  • Masszi T; Department of Haematology and Stem Cell Transplantation, St István and St László Hospital, Budapest, Hungary.
  • Spicka I; First Faculty of Medicine, First Medical Department, Clinical Department of Haematology, Charles University in Prague, Prague, Czech Republic.
  • Shpilberg O; Institute of Haematology, Assuta Medical Centre, Tel-Aviv, Israel.
  • Hajek R; Department of Haemato-oncology, FN Ostrava and Faculty of Medicine, Ostrava, Czech Republic.
  • Dmoszynska A; Medical University of Lublin, Lublin, Poland.
  • Paiva B; Centro de Investigación Médica Aplicada (CIMA), Clínica Universidad de Navarra, Pamplona, Spain.
  • Vidriales MB; IBMCC (USAL-CSIC), Hospital Universitario Salamanca, CIC, Salamanca, Spain.
  • Esteves G; Hospital de Dia de Hematologia, Hospital de Santa Maria, Lisbon, Portugal.
  • Stoppa AM; Institut Paoli-Calmettes, Marseille, France.
  • Robinson D; Janssen Global Services, LLC, Raritan, NJ, USA.
  • Chaturvedi S; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Ataman O; Division of Janssen-Cilag Limited, Janssen Research & Development, High Wycombe, UK.
  • Enny C; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Feng H; Janssen Research & Development, LLC, Spring House, PA, USA.
  • van de Velde H; Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium.
  • Viterbo L; Serviço de Onco-Hematologia, Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE), Porto, Portugal.
Br J Haematol ; 171(3): 344-54, 2015 Nov.
Article in En | MEDLINE | ID: mdl-26153365
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Stem Cell Transplantation / Induction Chemotherapy / Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2015 Document type: Article Affiliation country: Austria Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Stem Cell Transplantation / Induction Chemotherapy / Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2015 Document type: Article Affiliation country: Austria Country of publication: United kingdom